Recent progress in the discovery of small molecules for the treatment of amyotrophic lateral sclerosis (ALS)
Year: 2013
Type: article
Abstract: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder with few therapeutic options. While several gene mutations have been implicated in ALS, the exact cause of neuronal dysfunction is unknown and motor neurons of affected individuals display numerous cellular abnormalities. Ongoing efforts to develop novel ALS treatments involve the identification of small molecules targeting specific mechanisms of neuronal pathology, including glutamate excitotoxicity, mutant protein aggregation, endoplasmic reticulum (ER) stress, loss of trophic factors, oxidative stress, or neuroinflammation. Herein, we review recent advances in the discovery and preclinical characterization of lead compounds that may ultimately provide novel drugs to treat patients suffering from ALS.
DOI: 10.3762/bjoc.9.82
Institution: Sanford Burnham Prebys Medical Discovery Institute
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Funder: U.S. Department of Defense
Award: G4119534169
OpenAlex ID: W2008649097
